Numenos develops patient-centric biological world models by integrating individual patient data across all diseases simultaneously. This platform discovers invariant causal mechanisms underlying human biology rather than focusing on disease-specific correlations. The goal is to learn fundamental biological laws to enable the development of individualized therapeutic solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development methods face inefficiencies due to limited sample sizes and the high dimensionality of clinical trial data, hindering the applicability of machine learning and artificial intelligence, and resulting in lost potential for identifying effective treatments. Existing approaches often struggle to fully leverage the wealth of information contained within clinical trial data to guide decision-making and patient stratification.
Solution
NUMENOS offers an AI-driven platform, CURE, that enhances drug development by integrating and analyzing real-world data (RWD) and Phase I-IV clinical trial data. The CURE platform leverages a proprietary, integrated, and interpretable foundation model with over 100 million parameters to unravel causal and predictive biomarkers and targets. By revealing molecular fingerprints of patients most likely to benefit from a given therapy and disease mechanisms, CURE enables biomarker-driven target discovery, patient stratification, and reverse translation. This approach guides data-driven decision-making, potentially leading to faster trials, drug differentiation, and the prioritization of assets relevant to multiple indications.
Target Audience
The primary audience includes pharmaceutical companies, biotech firms, and research institutions involved in drug development, clinical trials, and biomarker discovery.
Features
- Integration and analysis of RWD and Phase I-IV clinical data
- Proprietary, integrated, and interpretable foundation model with over 100 million parameters
- Identification of causal and predictive biomarkers and targets
- Unraveling of disease progression mechanisms and biological mechanisms behind drug benefit
- Patient stratification based on molecular fingerprints
- Biomarker-driven reverse and forward translation for clinically driven target discovery